Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06756711

Combination of Supplements for Treating Autistic Spectrum Disorder

A pilot study to compare the efficacy of a combination of apitherapy supplements versus placebo in children with autistic spectrum disorder.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

3 year–14 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Clinica Aide Sante, Bucharest, Romania

Loading trial locations.

About this study

A prospective, double-blind, placebo-controlled, crossover, multicentre clinical study which will enrol up to 45 children diagnosed with ASD (enrolment will stop when 40 children have completed the study). Children ages 3-14 will be tested before and after administering the combination of active substances (3 months) and placebo (3 months). The duration of participation in the study for each child will be 6 months. The supplements tested consist of three products - a combination of apitherapy and plant extracts - which have been approved for sale as individual supplements for more than 5 years in Romania - Apicol 12 gamma, Laptisor de matca activat (Royal Jelly) and Telom R Cerebral. Participation in the study is free and all children will be comparatively evaluated with the ATEC and ASRS scales and three sets of blood tests.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age 3-14 years
  • diagnosed with typical or atypical autism spectrum disorder (F84.0 or F84.1) and received at least one therapeutic intervention before enrolling
  • the ability to follow an oral treatment, with TID/BID/QD administration
  • the availability to perform 3 sets of blood tests at a clinical laboratory within 6 months (initial, at 3- and 6-months)
  • the availability to perform 3 visits to the Investigator and 3 psychometric evaluations within 6 months

Exclusion criteria

  • patients enrolled in another interventional clinical trial currently or which ended less than 1 month prior to enrolling in this study
  • known allergy to hive products or one of the substances studied
  • inability to perform the study requirements (3 visits to the Investigator, 3 psychometric assessments, 3 sets of blood tests)
  • diagnosis of diabetes
  • history of seizures/epilepsy
  • administration of anticoagulants, antiplatelets, thrombolytic agents, low molecular weight heparins, anticonvulsants, insulin, monoamine oxidase inhibitors, non-steroidal anti-inflammatory drugs or thiazide diuretics
  • allergy to celery and other plants of the Fam. Apiaceaea (Umbelliferae)
  • abnormally elevated baseline (at V1) values of ferritin, homocysteine, HgbA1c, ESR

Treatment and study plan

A combination of apitherapy and plant extracts

Dietary Supplement

This combination contains the active comparator

Placebo Combination

Combination Product

A combination containing inert substances - placebo

Primary outcomes

  1. Modification on ATEC score

    Time frame: 3 months each of administration of active treatment and respectively placebo

    Total ATEC (Autism Treatment Evaluation Checklist) scores before and after each intervention, as well subscale scores; higher scores indicate worse status, score range between 0 (minimal, absence of pathology), to 180 - maximal intensity of symptoms

  2. Modification of ASRS scores

    Time frame: 3 months each of administration of active treatment and respectively placebo

    Scores on Autism Spectrum Rating Scales (ASRS) tests, total and 8 subscales will be compared before and after each intervention; total scores vary between 50-255, with higher score indicating more severe symptoms

Secondary outcomes

  1. NSE level modifications

    Time frame: 3 months each of administration of active treatment and respectively placebo

    Changes in the levels of serum Neuron-specific enolase (NSE) will be compared between the two arms, higher levels indicate higher neuronal destruction

Other outcomes

  1. Adverse effects

    Time frame: 3 months each of administration of active treatment and respectively placebo

    Adverse effects will be noted and compared for the two study arms

Sponsors and collaborators

Lead sponsor

Fundatia Bio-Forum

Other

Registry information

Acronym: APITSA

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jan 3, 2025
Registry last updated
Jan 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.